PRECISION BIOSCIENCES INC (DTIL) Stock News

USA - NASDAQ:DTIL - US74019P2074 - Common Stock

6 USD

-0.07 (-1.15%)

Last: 11/11/2025, 8:00:01 PM

5.85 USD

-0.15 (-2.5%)

After Hours: 11/11/2025, 8:00:01 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

DTIL Latest News, Press Relases and Analysis

All

Press Releases

9 days ago - By: Chartmill

News Image

Precision BioSciences Inc (NASDAQ:DTIL) Stock Falls After Q3 2025 Earnings and Revenue Miss

a day ago - By: Precision BioSciences, Inc.

Precision BioSciences Announces $75 Million Offering of Common Stock, Pre-Funded Warrants and Warrants

a day ago - By: Precision BioSciences, Inc.

Precision BioSciences Presents Late-Breaking Phase 1 PBGENE-HBV Data at AASLD The Liver Meeting® Showing Safety, Tolerability and Cumulative, Dose-Dependent Antiviral Activity in First Three Cohorts

9 days ago - By: Precision BioSciences, Inc.

Precision BioSciences Reports Third Quarter 2025 Financial Results and Provides Business Update

12 days ago - By: Precision BioSciences, Inc.

Precision BioSciences to Report Third Quarter 2025 Financial Results on November 3, 2025

a month ago - By: Precision BioSciences, Inc.

Precision BioSciences Announces Late-Breaking Oral Presentation for PBGENE-HBV at AASLD The Liver Meeting® 2025

a month ago - By: Precision BioSciences, Inc.

Precision BioSciences Announces Publication in Nucleic Acids Research Elucidating the Mechanisms for High Efficiency Gene Insertion in Dividing and Non-Dividing Cells Using ARCUS Nucleases

a month ago - By: Precision BioSciences, Inc.

Precision BioSciences Announces Opening of First Clinical Trial Site in U.S. for ELIMINATE-B Trial

a month ago - By: Precision BioSciences, Inc.

Precision BioSciences Announces Late-Breaking Poster Presentation at the 30th Annual International Congress of the World Muscle Society

2 months ago - By: Precision BioSciences, Inc.

Precision BioSciences Presents Data from the Phase 1 ELIMINATE-B Trial of PBGENE-HBV at the 6th International Coalition to Eliminate HBV Cure Symposium

2 months ago - By: Precision BioSciences, Inc.

Precision BioSciences Announces U.S. Patent Covering PBGENE-HBV for Chronic Hepatitis B and Updates Program Status

3 months ago - By: The Motley Fool

DTIL Revenue Drops 99%

3 months ago - By: Zacks Investment Research - Mentions: FEMY

Precision BioSciences (DTIL) Reports Q2 Loss, Lags Revenue Estimates

3 months ago - By: Precision BioSciences, Inc.

Precision BioSciences Reports Second Quarter 2025 Financial Results and Provides Business Update

3 months ago - By: Benzinga - Mentions: GSAT PGY ADV REAL ...

Earnings Scheduled For August 7, 2025

3 months ago - By: Zacks Investment Research - Mentions: IMNM

Immunome, Inc. (IMNM) Reports Q2 Loss, Beats Revenue Estimates

3 months ago - By: Precision BioSciences, Inc.

Precision BioSciences Announces Phase 1 Safety and Efficacy for Cohort 1, Lowest Dose Level in ELIMINATE-B, a First-In-Human Trial of PBGENE-HBV for Chronic Hepatitis B

3 months ago - By: Zacks Investment Research - Mentions: QGEN

Qiagen (QGEN) Matches Q2 Earnings Estimates

3 months ago - By: Precision BioSciences, Inc.

Precision BioSciences to Report Second Quarter 2025 Results on August 7, 2025

4 months ago - By: Precision BioSciences, Inc.

Precision BioSciences Receives FDA Orphan Drug Designation for PBGENE-DMD for the Treatment of Duchenne Muscular Dystrophy

4 months ago - By: Precision BioSciences, Inc.

Precision BioSciences Highlights New Preclinical Data for PBGENE-DMD Further Supporting Advancement of Novel Gene Editing Approach for the Treatment of Duchenne Muscular Dystrophy Towards Clinic

5 months ago - By: Stocktwits

Precision Bio's DMD Therapy Gets Rare Pediatric Status, But Stock Slides; Retail Crowd Sees ‘Good Risk-Reward’

5 months ago - By: Precision BioSciences, Inc.

Precision BioSciences Receives FDA Rare Pediatric Disease Designation for PBGENE-DMD for the Treatment of Duchenne Muscular Dystrophy

6 months ago - By: ACCESS Newswire - Mentions: ULY HTCR DGXX LWLG ...

Sidoti Events, LLC's Virtual May Micro-Cap Conference

6 months ago - By: Zacks Investment Research - Mentions: FBIO

Precision BioSciences (DTIL) Reports Q1 Loss, Lags Revenue Estimates

6 months ago - By: Precision BioSciences, Inc.

Precision BioSciences Reports First Quarter 2025 Financial Results and Provides Business Update

6 months ago - By: Zacks Investment Research - Mentions: ARMP

Armata Pharmaceuticals, Inc. (ARMP) Reports Q1 Loss, Lags Revenue Estimates

6 months ago - By: Precision BioSciences, Inc.

Precision BioSciences Accelerates Development of PBGENE-DMD Within its Wholly Owned Organic Pipeline and Highlights Pre-clinical Evidence at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

6 months ago - By: Benzinga

Uncovering Potential: Precision BioSciences's Earnings Preview

6 months ago - By: Zacks Investment Research - Mentions: AKYA

Akoya Biosciences (AKYA) Reports Q1 Loss, Misses Revenue Estimates

6 months ago - By: Precision BioSciences, Inc.

Precision BioSciences to Report First Quarter 2025 Results on May 15, 2025

6 months ago - By: Precision BioSciences, Inc.

Precision BioSciences Announces Presentation of Initial Safety Data from the Phase 1 ELIMINATE-B Trial Evaluating PBGENE-HBV at the 2025 European Association for the Study of the Liver Congress (EASL)

6 months ago - By: Zacks Investment Research - Mentions: DVAX

Dynavax Technologies (DVAX) Reports Q1 Loss, Misses Revenue Estimates

6 months ago - By: Precision BioSciences, Inc.

Precision BioSciences Announces Multiple Presentations for In Vivo Gene Editing Programs at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

7 months ago - By: Precision BioSciences, Inc.

Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)